Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Tema Etfs LLC

Key Points

• Tema Etfs LLC reduced its stake in Vertex Pharmaceuticals by 23.1%, now holding 8,448 shares worth approximately $4,096,000.
• Institutional investors own 90.96% of Vertex Pharmaceuticals' stock, indicating significant confidence from large financial entities.
• Vertex Pharmaceuticals reported a quarterly earnings per share of $4.52, exceeding analyst expectations and reflecting an 11.3% revenue increase year-over-year.

Tema Etfs LLC lowered its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 23.1% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 8,448 shares of the pharmaceutical company's stock after selling 2,533 shares during the period. Vertex Pharmaceuticals makes up approximately 1.2% of Tema Etfs LLC's investment portfolio, making the stock its 20th largest position. Tema Etfs LLC's holdings in Vertex Pharmaceuticals were worth $4,096,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the stock. Landscape Capital Management L.L.C. lifted its holdings in Vertex Pharmaceuticals by 171.0% during the 1st quarter. Landscape Capital Management L.L.C. now owns 3,477 shares of the pharmaceutical company's stock worth $1,686,000 after buying an additional 2,194 shares in the last quarter. Oak Associates Ltd. OH raised its holdings in shares of Vertex Pharmaceuticals by 4.4% in the 1st quarter. Oak Associates Ltd. OH now owns 4,771 shares of the pharmaceutical company's stock valued at $2,313,000 after purchasing an additional 200 shares in the last quarter. Oarsman Capital Inc. raised its holdings in shares of Vertex Pharmaceuticals by 4.2% in the 1st quarter. Oarsman Capital Inc. now owns 4,342 shares of the pharmaceutical company's stock valued at $2,105,000 after purchasing an additional 176 shares in the last quarter. B. Metzler seel. Sohn & Co. AG raised its holdings in shares of Vertex Pharmaceuticals by 289.2% in the 1st quarter. B. Metzler seel. Sohn & Co. AG now owns 314,343 shares of the pharmaceutical company's stock valued at $152,400,000 after purchasing an additional 233,584 shares in the last quarter. Finally, Paces Ferry Wealth Advisors LLC raised its holdings in shares of Vertex Pharmaceuticals by 9.4% in the 1st quarter. Paces Ferry Wealth Advisors LLC now owns 1,352 shares of the pharmaceutical company's stock valued at $655,000 after purchasing an additional 116 shares in the last quarter. Hedge funds and other institutional investors own 90.96% of the company's stock.

Wall Street Analysts Forecast Growth

VRTX has been the topic of several research analyst reports. JPMorgan Chase & Co. lifted their price target on shares of Vertex Pharmaceuticals from $515.00 to $517.00 and gave the stock an "overweight" rating in a research note on Monday, July 14th. Stifel Nicolaus cut their price objective on Vertex Pharmaceuticals from $494.00 to $455.00 and set a "hold" rating for the company in a research report on Tuesday, August 5th. Wells Fargo & Company raised Vertex Pharmaceuticals from an "equal weight" rating to an "overweight" rating and set a $460.00 price target on the stock in a research note on Wednesday, August 6th. Morgan Stanley set a $439.00 target price on shares of Vertex Pharmaceuticals and gave the company an "equal weight" rating in a report on Tuesday, August 5th. Finally, Cantor Fitzgerald dropped their price target on Vertex Pharmaceuticals from $535.00 to $485.00 and set an "overweight" rating for the company in a research report on Tuesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and thirteen have issued a Hold rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $497.10.

Vertex Pharmaceuticals Trading Down 0.3%

VRTX traded down $1.03 during trading on Friday, hitting $391.02. 1,309,844 shares of the company's stock were exchanged, compared to its average volume of 2,585,422. The stock has a 50 day moving average price of $433.35 and a 200 day moving average price of $458.70. Vertex Pharmaceuticals Incorporated has a 1 year low of $362.50 and a 1 year high of $519.88. The firm has a market cap of $100.25 billion, a P/E ratio of 27.95 and a beta of 0.44.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 EPS for the quarter, topping analysts' consensus estimates of $4.24 by $0.28. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The business had revenue of $2.94 billion for the quarter, compared to analysts' expectations of $2.90 billion. During the same period in the previous year, the company posted ($12.83) earnings per share. The business's revenue for the quarter was up 11.3% compared to the same quarter last year. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. Analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Insider Activity at Vertex Pharmaceuticals

In other news, Director Bruce I. Sachs bought 5,000 shares of Vertex Pharmaceuticals stock in a transaction dated Wednesday, August 6th. The shares were acquired at an average cost of $389.68 per share, with a total value of $1,948,400.00. Following the completion of the transaction, the director owned 45,000 shares in the company, valued at approximately $17,535,600. This trade represents a 12.50% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.20% of the company's stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.